NYSE:IQV - Iqvia Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$136.31 -1.05 (-0.76 %)
(As of 04/26/2019 09:36 AM ET)
Previous Close$137.36
Today's Range$136.31 - $136.31
52-Week Range$91.57 - $146.10
Volume5,516 shs
Average Volume1.27 million shs
Market Capitalization$26.96 billion
P/E Ratio26.62
Dividend YieldN/A
Beta0.85
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
CUSIPN/A
Phone919-998-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.41 million
Cash Flow$11.0372 per share
Book Value$34.76 per share

Profitability

Net Income$259 million

Miscellaneous

Employees58,000
Market Cap$26.96 billion
Next Earnings Date5/1/2019 (Confirmed)
OptionableOptionable

Iqvia (NYSE:IQV) Frequently Asked Questions

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) posted its quarterly earnings data on Thursday, February, 14th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.47 by $0.03. The medical research company had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.62 billion. Iqvia had a net margin of 2.49% and a return on equity of 14.25%. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.40 EPS. View Iqvia's Earnings History.

When is Iqvia's next earnings date?

Iqvia is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Iqvia.

How can I listen to Iqvia's earnings call?

Iqvia will be holding an earnings conference call on Wednesday, May 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8009094261.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia issued an update on its FY19 earnings guidance on Thursday, February, 14th. The company provided earnings per share (EPS) guidance of $6.20-6.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.28. The company issued revenue guidance of $10.9-11.25 billion, compared to the consensus revenue estimate of $10.91 billion.Iqvia also updated its FY 2019 guidance to $6.20-6.40 EPS.

What price target have analysts set for IQV?

17 Wall Street analysts have issued 12 month price objectives for Iqvia's shares. Their predictions range from $120.00 to $170.00. On average, they expect Iqvia's stock price to reach $147.20 in the next twelve months. This suggests a possible upside of 7.2% from the stock's current price. View Analyst Price Targets for Iqvia.

What is the consensus analysts' recommendation for Iqvia?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 3 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

Has Iqvia been receiving favorable news coverage?

News coverage about IQV stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iqvia earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days.

Who are some of Iqvia's key competitors?

What other stocks do shareholders of Iqvia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), Micron Technology (MU), NIC (EGOV), Workday (WDAY) and Aegean Marine Petroleum Network (ANW).

Who are Iqvia's key executives?

Iqvia's management team includes the folowing people:
  • Mr. Ari Bousbib, Chairman, Pres & CEO (Age 58)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
  • Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)

Who are Iqvia's major shareholders?

Iqvia's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Ardevora Asset Management LLP (0.14%), Strs Ohio (0.14%), Arvest Bank Trust Division (0.11%), Braun Stacey Associates Inc. (0.06%), Jag Capital Management LLC (0.06%) and DNB Asset Management AS (0.06%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Dennis B Ph D Gillings, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

Which institutional investors are selling Iqvia stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Meeder Asset Management Inc., Arvest Bank Trust Division, DNB Asset Management AS, Retirement Systems of Alabama, Oakbrook Investments LLC, Telos Capital Management Inc. and Braun Stacey Associates Inc.. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

Which institutional investors are buying Iqvia stock?

IQV stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio, Columbus Circle Investors, Jag Capital Management LLC, Pennsylvania Trust Co, Pennsylvania Trust Co, Nisa Investment Advisors LLC, Rosenblum Silverman Sutton S F Inc. CA and Deltec Asset Management LLC. View Insider Buying and Selling for Iqvia.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $137.36.

How big of a company is Iqvia?

Iqvia has a market capitalization of $27.17 billion and generates $10.41 million in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.

What is Iqvia's official website?

The official website for Iqvia is http://www.iqvia.com.

How can I contact Iqvia?

Iqvia's mailing address is 4820 EMPEROR BLVD., DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]


MarketBeat Community Rating for Iqvia (NYSE IQV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  420 (Vote Outperform)
Underperform Votes:  372 (Vote Underperform)
Total Votes:  792
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel